Ignite Creation Date:
2024-05-06 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 1:53 PM
Study NCT ID:
NCT04699643
Status:
UNKNOWN
Last Update Posted:
2021-01-07
First Post:
2020-12-29
Brief Title:
FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors
Sponsor:
EverNov Medicines Zhuhai Hengqin Co Ltd
Organization:
EverNov Medicines Zhuhai Hengqin Co Ltd
Organization Data
Organization:
EverNov Medicines Zhuhai Hengqin Co Ltd
Class:
INDUSTRY
Study ID:
EVER401-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
EverNov Medicines Zhuhai Hengqin Co Ltd
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Medidata Solutions | INDUSTRY |